Sisvel and Mitsubishi, and Xiaomi sign patent licensing deal to settle ongoing litigations

Recently, Sisvel and Mitsubishi jointly announced that the companies have entered into a patent license agreement covering the standard-essential patents (SEP) of Mitsubishi Electric and Sisvel in the field of mobile communication. This deal brings to an end the global dispute between the three companies, which has spanned the courts in China, Germany, Italy, the Netherlands, and […]

DelSiTech and Visus Therapeutics enter into Patent Licensing Arrangement

Recently, DelSiTech Ltd. (“DelSiTech”), a Finland-based drug delivery company entered into a patent licensing agreement over DelSiTech’s patents with Visus Therapeutics (“Visius”), a US-based company. This is a worldwide exclusive licensing agreement. Both companies are working on six development programs for eye care solutions targeting the management of ocular diseases of the back and front of the […]

ERS Genomics Licenses CRISPR-Cas9 patent and technology to Cellular Engineering Technologies

Recently, Dublin, Ireland-based biotechnology company, ERS Genomics Limited (“ERS”), has signed a nonexclusive license agreement with Iowa-based Cellular Engineering Technologies (“CET”) to grant access to its CRISPR-Cas9 patent portfolio. The financial terms of the agreement were not disclosed. ERS was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property for use as a research platform. ERS […]

Sun Pharma and Celegene Settle Patent Dispute over Lenalidomide (Revlimid®)

Settling an over three old patent infringement dispute, Indian pharmaceutical major, Sun Pharmaceuticals and its subsidiary, including US subsidiary (“Sun”), has reached a settlement with Celgene Corporation (“Celgene”), a subsidiary of pharmaceutical major Bristol Myers Squibb (BMS), to resolve and settle the patent litigation regarding submission of an Abbreviated New Drug Application (ANDA) for a […]

Bajaj Healthcare Files Compulsory License with Indian Patent Office for Baricitinib

Recently, drug manufacturer, Bajaj Healthcare Limited issued a press release stating that they have filed a compulsory license application with the Indian Patent Office seeking permission to manufacture both active pharmaceutical ingredients (raw materials) and formulation of Baricitinib under the Indian Patents Act. Baricitinib is essentially a drug approved in the US and European Union, for the […]

Elli Lilly Enters into Licensing Deals with Indian Companies

Recently, Elli Lilly, a US-based major Pharmaceutical company, has entered into licensing agreements with a number of Indian drug manufacturers for the manufacture of and supply of Baricitinib in India which is showing promise as a drug for the treatment of Covid-19. The licensing agreement with Eli Lilly is voluntary, royalty-free, and non-exclusive in nature for the […]

Concept Of Compulsory Licensing Under The Patents Act

An inventor is allotted with the patent right in exchange for disclosing its invention. Apart from the inventor of that patent, the public is being benefited most. Therefore it must be taken into consideration that the invention is made surely available to the public. But there seems to a danger of misuse of such monopolistic […]

InterDigital vs Xiaomi: An interesting case on Confidentiality Club in Standard Essential Patents Litigation

Recently, the Delhi High Court decided on a patent infringement suit filed by Interdigital Technology Corporation (“InterDigital”), a US-based mobile and video Research & Development company, against Xiaomi Corporation (“Xiaomi”), a China-based internet and telecommunication company. An interesting aspect that was put forth for the consideration of the single judge Bench of the Delhi High Court is […]

InterDigital vs Xiaomi: An interesting case on Confidentiality Club in Standard Essential Patents Litigation

Recently, the Delhi High Court decided on a patent infringement suit filed by Interdigital Technology Corporation (“InterDigital”), a US-based mobile and video Research & Development company, against Xiaomi Corporation (“Xiaomi”), a China-based internet and telecommunication company. An interesting aspect that was put forth for the consideration of the single judge Bench of the Delhi High […]